Anzeige
Mehr »
Login
Montag, 08.03.2021 Börsentäglich über 12.000 News von 659 internationalen Medien
Mit Vollgas in die Zukunft! Taat Lifestyle zündet den News-Turbo!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von PMLiVE

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
01.03.Building meaningful customer engagement through data-driven digital insights
26.02.FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
26.02.Regeneron's COVID-19 antibody cocktail shows 'clear efficacy'
26.02.Merck to acquire Pandion Therapeutics for $1.85bn
26.02.UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
26.02.Protalix, Chiesi's monthly treatment PRX-102 shows benefit in Fabry disease
26.02.bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
26.02.The five-step, rare disease-ready checklist
25.02.FDA briefing document backs J&J's one-dose COVID-19 vaccine
25.02.Pfizer/BioNTech vaccine is 94% effective after second dose, major real-world study finds
25.02.Moderna announces plans for COVID-19 variant-specific booster jabs and new production targets
25.02.FDA updates guidance for COVID-19 vaccine makers addressing new variants
25.02.Integrating competitive intelligence into business development, licensing and M&A strategy
25.02.Communiqué Awards 2021 entry deadline is two weeks away!
25.02.Dan Carucci becomes global chief medical officer of McCann Health
24.02.FDA fast-tracks review of Incyte's Jakafi for chronic GVHD
24.02.Sanofi, Regeneron's Libtayo scores first-line NSCLC approval in the US
24.02.bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
24.02.Reaching patients and HCPs during the pandemic
23.02.WHO agrees to no-fault compensation for rare serious side effects from COVAX-distributed vaccines
23.02.First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
23.02.AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail
23.02.UK approval for Seagen's oral HER2 inhibitor Tukysa
23.02.Back to the future
22.02.EU set to contribute €1bn to COVAX